Zacks Investment Research upgraded shares of Lantheus (NASDAQ:LNTH) from a hold rating to a buy rating in a research note issued to investors on Friday morning. Zacks Investment Research currently has $26.00 price objective on the medical equipment provider’s stock.
According to Zacks, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States. “
A number of other brokerages also recently commented on LNTH. Jefferies Group lifted their price objective on Lantheus from $22.00 to $27.00 and gave the stock a buy rating in a research report on Friday, November 3rd. Credit Suisse Group lifted their price objective on Lantheus from $19.00 to $23.00 and gave the stock a neutral rating in a research report on Friday, November 3rd. BidaskClub upgraded Lantheus from a hold rating to a buy rating in a research report on Wednesday, December 27th. ValuEngine downgraded Lantheus from a buy rating to a hold rating in a research report on Friday, December 1st. Finally, Wells Fargo & Co upgraded Lantheus from a market perform rating to an outperform rating in a research report on Thursday, November 2nd. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of Buy and an average price target of $24.50.
Lantheus (NASDAQ:LNTH) opened at $23.48 on Friday. Lantheus has a 1 year low of $7.95 and a 1 year high of $24.10. The firm has a market capitalization of $880.45, a P/E ratio of 28.99, a PEG ratio of 1.52 and a beta of 0.94. The company has a debt-to-equity ratio of -3.41, a current ratio of 2.96 and a quick ratio of 2.46.
Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported $0.24 EPS for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.04. Lantheus had a negative return on equity of 46.45% and a net margin of 9.59%. The firm had revenue of $79.94 million for the quarter, compared to the consensus estimate of $77.18 million. During the same quarter last year, the business posted $0.15 earnings per share. The firm’s revenue was up 9.4% compared to the same quarter last year. sell-side analysts expect that Lantheus will post 1.05 EPS for the current year.
In other Lantheus news, insider Michael P. Duffy sold 21,655 shares of the firm’s stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $22.40, for a total transaction of $485,072.00. Following the completion of the sale, the insider now owns 156,784 shares of the company’s stock, valued at $3,511,961.60. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Michael P. Duffy sold 11,917 shares of the firm’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $21.63, for a total value of $257,764.71. Following the sale, the insider now directly owns 152,301 shares of the company’s stock, valued at approximately $3,294,270.63. The disclosure for this sale can be found here. In the last quarter, insiders have sold 44,886 shares of company stock worth $986,201. 2.30% of the stock is currently owned by company insiders.
Hedge funds have recently bought and sold shares of the business. Quantbot Technologies LP acquired a new stake in Lantheus during the second quarter worth $117,000. Sei Investments Co. increased its stake in Lantheus by 189.6% during the third quarter. Sei Investments Co. now owns 7,829 shares of the medical equipment provider’s stock worth $139,000 after acquiring an additional 5,126 shares during the last quarter. Teachers Retirement System of The State of Kentucky acquired a new stake in Lantheus during the second quarter worth $141,000. BNP Paribas Arbitrage SA acquired a new stake in Lantheus during the second quarter worth $146,000. Finally, LS Investment Advisors LLC increased its stake in Lantheus by 47.1% during the third quarter. LS Investment Advisors LLC now owns 9,306 shares of the medical equipment provider’s stock worth $166,000 after acquiring an additional 2,981 shares during the last quarter. 91.91% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This story was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://transcriptdaily.com/2018/01/16/lantheus-lnth-raised-to-buy-at-zacks-investment-research.html.
Lantheus Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.